November 2008 Br J Cardiol 2008;15:307-11
Helen Williams, Rachel Hughes, Lucy Simkins, Katie Hatton, Michael Currie, Holly Chong, Victoria Hill, Christopher Boddy, Sara Nelson, Claire Foreman on behalf of the Cardiac Prescribing Forum of the South East London Cardiac and Stroke Network (SELCSN)
Introduction Over the past five years, clopidogrel, often in combination with aspirin, has become standard therapy for patients with a number of cardiovascular disorders. Dual therapy with aspirin and clopidogrel is particularly important in the management of ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and following intra-coronary stent placement. Evidence from clinical trials has demonstrated that the benefits of dual therapy are greatest where aspirin and clopidogrel are initiated early following an acute event or prior to a percutaneous coronary intervention (PCI). The optimal duration of clo
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits